Trim 35-40% at $148.30; stop at $142; two-stage re-engagement through Q3 FY26
Underweight EMR on four convergent pillars: (1) confirmed technical deterioration with MACD histogram at -0.91 deepening and lower-high/lower-low sequence from $163.82 to $148.30, (2) macro headwind from 1.46% dividend yield below 5% 10-year Treasury with 94% Polymarket probability of zero Fed cuts in 2026 pressuring multiples, (3) balance sheet fragility with net interest expense up 166% YoY (-$89M to -$237M), goodwill at 66% of assets, and tangible book of -$7.37B, and (4) forward EPS bridge execution risk requiring ~58% expansion from $4.57 TTM to $7.24. The $142 stop at the 200 SMA ($142.38) provides ~1.5 ATRs of room while remaining structurally grounded. Trim 35-40% rather than full liquidation because the structural floor (67-69 year dividend streak, $3.7B TTM FCF covering dividend 3x, 1.91x net debt/EBITDA) preserves asymmetric upside into the Q3 print catalyst.
| Position | Action |
|---|---|
| Current $148.30 levels | Trim 35-40% relative to benchmark weight as a single tranche |
EMR's recent pullback from $163.82 to $148.30 represents a healthy 9.5% consolidation, not a breakdown, offering a high-conviction entry into a transformed industrial compounder riding an AI infrastructure tailwind with a clear earnings inflection from $4.57 TTM EPS to $7.24 forward.
| Indicator | Value | Signal |
|---|---|---|
| Latest Close | $148.30 | neutral |
| 10 EMA | $151.13 | bearish |
| 50 SMA | $150.01 | bearish |
| 200 SMA | $142.38 | bullish |
| MACD | -0.91 | bearish |
| MACD Signal | 0.00 | bearish |
| MACD Histogram | -0.91 | bearish |
| RSI | 43.35 | neutral |
| Bollinger Upper | $162.01 | bearish |
| Bollinger Middle | $153.83 | bearish |
| Bollinger Lower | $145.64 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Re-enter second half of position
Forward valuation is reasonable given the earnings inflection; TTM P/E is distorted by non-cash charges
↩ rebuts: “The P/E Is Rich at 32x”
EV: Target: retest of $163, then $170+ on Aspen Tech margin confirmation and rates relief. Entry zone: $145-$148.
EMR is a cyclical industrial stock priced for perfection—the 20.5x forward P/E is expensive in a 5% rate regime, goodwill represents 66% of assets with negative tangible equity, and the stock hasn't even reached oversold conditions yet.
EV: -$108 (downside scenario based on $6.00 EPS at 18x P/E) · concedes: EMR is a fine business transformed into a credible industrial-software hybrid; If price reclaims $151-$153 with conviction, the bear would reconsider; A confirmed bottoming pattern (higher low on price + higher low on RSI) with 10Y below 4.5% would change the view
→ vs neutral: HOLD stance with $145 scale-in target is 'intellectual cowardice dressed up as balance' — cannot scale in from full position; must trim first to create capital for redeployment
→ vs conservative: Waiting for bounce above $151 and 'confirmation' before trimming is sunk-cost mindset — long-term trend intact does not require riding every drawdown; asymmetric downside unprotected if 200 SMA breaks
| neutral |
| VWMA | $152.11 | bearish |
| ATR | $3.93 | neutral |
| Volume | 2.06M | neutral |
Support: 145.64 · 142.38 · 135 · 137 | Resistance: 151.13 · 153.83 · 162.01
The report assigns a HOLD bias, recommending investors wait for either a confirmed bounce above $151 with MACD turning positive, or a decisive test below the critical $142 support (200 SMA) before committing to a directional position. The overall bias is neutral-to-cautiously-bearish in the short term within a bullish long-term framework, with the $142 level identified as the line in the sand—holding it preserves the uptrend while losing it would signal a more serious regime change.
Market Cap
$82.72B
P/E (TTM)
32.45
Forward P/E
20.47
PEG Ratio
1.75
P/B
4.06
EPS (TTM)
$4.57
Forward EPS
$7.24
Dividend Yield
1.46%
Beta
1.23
52-Wk Range
$122.64 – $166.35
50-Day Avg
$150.11
200-Day Avg
$143.19
Revenue FY2025
18,016 ($M)
Gross Profit FY2025
9,519 ($M)
Operating Income FY2025
3,532 ($M)
Operating Margin FY2025
19.6%
Net Income (Continuing) FY2025
2,238 ($M)
Diluted EPS (Continuing) FY2025
$4.04
Cash & Equivalents FY2025
1.54 ($B)
Goodwill FY2025
18.19 ($B)
Intangibles (ex-Goodwill) FY2025
9.46 ($B)
Total Assets FY2025
41.96 ($B)
Total Debt FY2025
13.76 ($B)
Net Debt FY2025
11.57 ($B)
Total Stockholders' Equity FY2025
20.28 ($B)
Tangible Book Value FY2025
(7.37) ($B)
Operating Cash Flow FY2025
3,098 ($M)
Capex FY2025
(431) ($M)
Free Cash Flow FY2025
2,667 ($M)
Acquisitions FY2024
(8,342) ($M)
Dividends Paid FY2025
(1,192) ($M)
Share Repurchases FY2025
(1,167) ($M)
Net Debt Issuance FY2025
+5,241 ($M)
Gross Margin TTM
53.2%
Operating Margin TTM
26.9%
Net Margin TTM
13.8%
ROE TTM
12.8%
ROA TTM
6.9%
FCF Margin TTM
~19.9%
Dividend Paid Annual
$1.19B
Net Debt/EBITDA
~1.9x
Current Ratio FY2025
0.90
Debt/Equity FY2025
~67.7%
Amortization of Acquired Intangibles FY2025
~$1.17B
Annual Restructuring Charges
$300-350M
Unusual Items Drag Annual
$169-442M
Strengths
Concerns
Emerson Electric has successfully transformed from a diversified conglomerate into a focused automation solutions provider, anchored by Aspen Tech (industrial software) and National Instruments (test & measurement). The company's FY2025 results show revenue of $18.02B with operating margin expansion to 19.6%, driven by software-embedded business model with superior margins (53.2% gross, 26.9% operating) versus industrial peers. The critical valuation signal is the TTM-to-forward EPS gap ($4.57 to $7.24), with forward P/E of 20.47x reasonable given 9.3% revenue CAGR and FCF margin of ~20%. Balance sheet has become intangible-heavy post-acquisitions (66% of assets), with net debt at $11.57B and negative tangible book value, creating goodwill impairment risk but manageable leverage at 1.9x Net Debt/EBITDA. Capital allocation has been shareholder-friendly with $1.19B dividends and $1.17B buybacks funded entirely from FCF. The trade works if Aspen Tech synergies deliver; risk-reward is balanced with 32x TTM multiple, leaning slightly positive at current levels and more attractive on a pullback to ~$143.
Macro: 10-year Treasury crossed 5% (multi-year high) with equities retreating and precious metals selling off; crude oil extending gains (stagflationary flavor); Polymarket pricing 94% probability of zero Fed cuts in 2026 (+1.4pp WoW) and 10% probability of US recession by year-end 2026 (+3.0pp WoW). The macro regime is restrictive but not collapsing growth — a "grind-higher-with-multiple-headwind" backdrop historically constructive for industrial cash flow but hostile for industrial multiples.